Loading
Prescient Therapeutics Limited Stock: price and insider trades · Australia
3 insiders bought €17k of shares over the last 90 days, the latest filed 06 Oct 2026.
Cluster: 3 buyers in 30 daysPrescient Therapeutics Limited: what insiders have been doing
Headquartered in Melbourne, Prescient Therapeutics Limited is a listed company and traces its origins to 2014. Filings by its managers are published through ASX. In the past year (18 October 2025 to 18 October 2026), 3 filings came from 3 insiders.
No insider sold shares on the market over the period. Instead, the filings list 3 purchases totalling €17k, made by 3 insiders. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 3 senior executives. At €7,981, the purchase published on 6 October 2026 by Dr Gavin Shepherd is the largest of the period.
Within a 30-day window, 1 purchase overlapped with buying by a second insider. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The clock since the last published purchase (6 October 2026) now reads 12 days. The median gap between a trade and its publication by ASX is 6 days. Until a filing is published, the market cannot know about the trade.
With 3 filings in twelve months, the company is in line with the median of 3 filings across the 2,526 companies we follow on the same exchange. Over the whole record (from 2026), the tally stands at 3 purchases and no sales.
Source: insider filings from ASX. Past trades are no guide to future returns.
Insider Decl.
3
Thresholds
n/a
Buy Volume
€17,189
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleDr Gavin Shepherd1 buy
James Campbell1 buy
Melanie Farris1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended June 2026 · cache
A$0.07
Analyst consensus
Income statement
EBITDA-A$7M
Net income-A$7M-202.9% margin
Valuation
P/Book4.6x
Beta0.85
Balance sheet & cash
Market capA$74.4M
Total debtA$223k
Free Cash Flow-A$7.2M
Debt / Equity2%
Profitability & ownership
ROE-54.7%
ROA-28.9%
% insiders12.8%
% institutions0.8%
Last declaration on 6 October 2026
Declarations3 total
200,000 shares@ A$0.065100.0% of flowShareASXISIN AU000000PTX3ASX:2924-03144815-3A703404
Canonical exit: 29 Dec 2026 (T+90)
76,923 shares@ A$0.0650.0068% mcap100.0% of flowShareASXISIN AU000000PTX3ASX:2924-03144814-3A703403
Canonical exit: 29 Dec 2026 (T+90)
153,846 shares@ A$0.0650.014% mcap100.0% of flowShareASXISIN AU000000PTX3ASX:2924-03144813-3A703401
Canonical exit: 29 Dec 2026 (T+90)
3 of 3 declarations
About Prescient Therapeutics Limited
Prescient Therapeutics Limited is a biopharmaceutical company focused on developing innovative cancer treatments. It is listed on the Australian Securities Exchange (ASX).
